Drugs / DIELEN® Protect
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07039747 | Apr 2025 → Feb 2027 expected | irritable bowel syndrome | University Hospital, Rouen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIELEN Protect | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07039747 ↗ |
| Modality | Other / unclassified | “The Dielen® Protect product formulated on the basis of the results of this study combines glutamine and Gabolysat® to provide a comfort solution for IBS patients.” NCT07039747 ↗ |
| Route | Oral | “Our working hypothesis is that patients suffering from moderate or severe IBS could benefit from oral supplementation with DIELEN Protect to improve the symptoms associated with IBS.” NCT07039747 ↗ |